<DOC>
	<DOCNO>NCT00258180</DOCNO>
	<brief_summary>RATIONALE : Cyclophosphamide may help control symptoms autoimmune enteropathy . PURPOSE : This phase II trial study well cyclophosphamide work treat young patient severe autoimmune enteropathy .</brief_summary>
	<brief_title>Cyclophosphamide Treating Young Patients With Severe Autoimmune Enteropathy</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine rate treatment-free remission young patient severe autoimmune enteropathy treat high-dose cyclophosphamide . Secondary - Determine toxic effect drug patient . OUTLINE : Patients receive cyclophosphamide IV 1 hour day 1-4 . Patients receive filgrastim ( G-CSF ) IV subcutaneously daily begin day 10 continue 3 day blood count recover . After completion study treatment , patient follow periodically 1½ year . PROJECTED ACCRUAL : A total 7-11 patient accrue study .</detailed_description>
	<mesh_term>Diarrhea</mesh_term>
	<mesh_term>Intestinal Diseases</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis severe autoimmune enteropathy Condition resistant conventional therapy Histologic evidence severe villous atrophy intense lymphocytic infiltrate lamina propria small intestinal biopsy within past 3 month Disease fail respond ≥ 2 month corticosteroid therapy dose ≥ 0.5 mg/kg/day ≥ 40 mg/day patient &gt; 20 kg AND 1 follow therapy : Cyclosporine result ≥ 1 whole blood level &gt; 200 ng/mL Tacrolimus result ≥ 1 whole blood level 5 ng/mL At least 50 % estimate caloric need provide parenteral nutrition History intractable diarrhea , define frequent watery stool &gt; 3 month respond dietary restriction No celiac disease , define history positive antiendomysial antibody tissue transglutaminase antibody No primary immunodeficiency xlinked autoimmunityallergy dysregulation PATIENT CHARACTERISTICS : Performance status Lansky 60100 % Life expectancy Not specify Hematopoietic Not specify Hepatic Not specify Renal Not specify Cardiovascular Ejection fraction ≥ 40 % OR shorten fraction ≥ 20 % Pulmonary FVC FEV_1 ≥ 50 % predict ( patient &gt; 8 year age ) No clinically abnormal pulmonary function abnormal pulse oximetry ( patient ≤ 8 year age ) Other Not pregnant Negative pregnancy test Fertile patient must use effective contraception least 9 month completion study treatment No known chromosomal abnormality PRIOR CONCURRENT THERAPY : Biologic therapy No immunization least 6 month completion study treatment Endocrine therapy See Disease Characteristics At least 5 day since prior corticosteroid No concurrent dexamethasone antiemetic Other At least 5 day since prior immunosuppressive medication ( e.g. , tacrolimus cyclosporine )</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>unspecified childhood solid tumor , protocol specific</keyword>
	<keyword>gastrointestinal complication</keyword>
	<keyword>diarrhea</keyword>
</DOC>